Included support
- +Hospital matching
- +Record review
- +Care coordination
- +Travel support
- +Interpretation support

CAR-T cell therapy may be considered in children with relapsed/refractory B-cell acute lymphoblastic leukemia or persistent MRD positivity, with CD19/CD22 as common targets. The decision depends on antigen expression, previous treatment and relapse risk, whether bridging therapy is needed, organ fun
24-72h
Response window
Approx. $5,400
Treatment fee
Peking Union Medical College Hospital - Beijing - Grade 3A
Ruijin Hospital - Shanghai - Grade 3A
West China Hospital - Chengdu - Grade 3A
Let us coordinate the treatment journey with you.
CAR-T is based on the patient's own or, if applicable, donor T cells, which are genetically modified in vitro to obtain a chimeric antigen receptor, commonly targeting CD19 or CD22. Usually, after collection and preparation are completed, a short course of lymphodepleting preconditioning is given, and then the expanded CAR-T cells are returned intravenously; during hospitalization, body temperature, blood pressure, neurological signs, and laboratory indicators are closely monitored, and supportive treatment is given. The overall goal is to maintain organ stability while controlling the lesions. The above is general health information, not medical advice; the specifics are subject to specialist assessment and hospital protocols.
CAR-T is based on the patient's own or, if applicable, donor T cells, which are genetically modified in vitro to obtain a chimeric antigen receptor, commonly targeting CD19 or CD22. Usually, after collection and preparation are completed, a short course of lymphodepleting preconditioning is given, and then the expanded CAR-T cells are returned intravenously; during hospitalization, body temperature, blood pressure, neurological signs, and laboratory indicators are closely monitored, and supportive treatment is given. The overall goal is to maintain organ stability while controlling the lesions. The above is general health information, not medical advice; the specifics are subject to specialist assessment and hospital protocols.

Considering screening and collection, cell preparation, hospitalization, and post-discharge follow-up, it is recommended to stay in China for approximately 5–8 weeks; subject to the actual process and assessment.

Tell us about your Pediatric Leukemia case and we will help match you with the right hospital, specialist, and travel pathway.